Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
YEHUD, Israel, September 10, 2013 /PRNewswire/ --
Treato, the source of "patient voice" intelligence from across the social web, today announced the new version of its flagship Treato Pharma platform for pharmaceutical companies and agencies.
Treato's proprietary big data technology platform extracts real-time patient insights about drugs, conditions and treatments from over 1.5 billion health-related discussions posted on thousands of blogs, forums and communities online. With Treato Pharma, customers have access to aggregated data about patient experiences, perceptions and attitudes. Treato Pharma's deep analytics capability then automatically turns this information into crystallized insights for understanding patient decision making, switching behaviors and competitive opportunities.
The new version reinforces Treato Pharma's position as the first-ever patient intelligence service designed specifically for the health and life sciences industries. Key features and benefits include:
"Treato Pharma continues to evolve as the go-to-platform for bringing the patient voice into the pharma boardroom - along with meaningful intelligence and predictive capabilities that can significantly impact product and market strategy," said Ido Hadari, CEO of Treato, "Now pharmaceutical executives can get an unmediated 'big picture' view of the patient insights that matter most for driving better, faster and more effective decisions to meet specific business goals."
Increasingly, pharmaceutical companies are turning to the online social space as a means for learning about the needs and wants of patients. According to a 2012 social media report by PwC's Health Research Institute, 42% of consumers have used social media to access health-related information, including consumer reviews of treatments, with another 25% posting about their own health experience. The study goes on to suggest that companies can benefit from integrating the insights that are available about their products and services through social media into their business strategies. The PwC study was based on a survey of 1060 US adults.
Treato Pharma leverages Treato's deep expertise in Natural Language Processing, extensive medical ontologies and big data analytics infrastructure to translate massive amounts of unstructured user-generated content (UGC) by patients and caregivers into meaningful brand insights. These are delivered via data visualization tools like drillable infographics, charts and graphs that can be immediately and easily understood.
In April Treato raised $14.5 million in an investment round led by OrbiMed Israel Partners, and New Leaf Venture Partners, and including existing investors Reed Elsevier Ventures and Western Technology Investments. The investment will help expedite the company's US expansion and ongoing development of its offering.
Treato is the source for real-time "patient voice" intelligence, collected from billions of patient conversations across the social web. Treato turns these social health experiences into meaningful insights through its free patient website Treato.com and professional Treato Pharma platform designed specifically for the health and life sciences industries.
Treato is privately held and backed by leading funds including Reed Elsevier Ventures, OrbiMed Partners, New Leaf Venture Partners and Western Technology Investments.
For more information about Treato or to learn more about Treato Pharma and new feature enhancements please contact:
©2012 PR Newswire. All Rights Reserved.